LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society.

    Blainey, Marc G

    Journal of religion and health

    2014  Volume 54, Issue 1, Page(s) 287–302

    Abstract: Santo Daime, a Brazilian religion organized around a potent psychoactive beverage called ayahuasca, is now being practiced across Europe and North America. Deeming ayahuasca a dangerous "hallucinogen," most Western governments prosecute people who ... ...

    Abstract Santo Daime, a Brazilian religion organized around a potent psychoactive beverage called ayahuasca, is now being practiced across Europe and North America. Deeming ayahuasca a dangerous "hallucinogen," most Western governments prosecute people who participate in Santo Daime. On the contrary, members of Santo Daime (called "daimistas") consider ayahuasca a medicinal sacrament (or "entheogen"). Empirical studies corroborate daimistas' claim that entheogens are benign and can be beneficial when employed in controlled contexts. Following from anthropology's goal of rendering different cultural logics as mutually explicable, this article intercedes in a misunderstanding between policies of prohibition and an emergent subculture of entheogenic therapy.
    MeSH term(s) Banisteriopsis ; Brazil ; Ceremonial Behavior ; Cultural Characteristics ; Drug and Narcotic Control ; Hallucinogens ; Humans ; Plant Extracts/adverse effects ; Plant Extracts/therapeutic use ; Religion ; Religion and Medicine ; Religion and Psychology ; Spiritual Therapies
    Chemical Substances Hallucinogens ; Plant Extracts
    Language English
    Publishing date 2014-01-30
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2017250-3
    ISSN 1573-6571 ; 0022-4197
    ISSN (online) 1573-6571
    ISSN 0022-4197
    DOI 10.1007/s10943-014-9826-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.

    Rosenblat, Joshua D / Meshkat, Shakila / Doyle, Zoe / Kaczmarek, Erica / Brudner, Ryan M / Kratiuk, Kevin / Mansur, Rodrigo B / Schulz-Quach, Christian / Sethi, Rickinder / Abate, Amanda / Ali, Shaun / Bawks, Jordan / Blainey, Marc G / Brietzke, Elisa / Cronin, Victoria / Danilewitz, Jessica / Dhawan, Shalini / Di Fonzo, Anthony / Di Fonzo, Melissa /
    Drzadzewski, Pawel / Dunlop, William / Fiszter, Hajnalka / Gomes, Fabiano A / Grewal, Smrita / Leon-Carlyle, Marisa / McCallum, Marilyn / Mofidi, Niki / Offman, Hilary / Riva-Cambrin, Jeremy / Schmidt, Joel / Smolkin, Mark / Quinn, Joan M / Zumrova, Andrea / Marlborough, Michelle / McIntyre, Roger S

    Med (New York, N.Y.)

    2024  Volume 5, Issue 3, Page(s) 190–200.e5

    Abstract: Background: Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, ...

    Abstract Background: Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations. Our aim was to determine the feasibility of PAP in a complex population, including high levels of treatment resistance in major depressive and bipolar disorder and patients with baseline suicidality and significant comorbidity. We also evaluated flexible repeated doses over a 6-month period.
    Methods: Adults with treatment-resistant depression as part of major depressive or bipolar II disorder without psychosis or a substance use disorder were eligible to participate. Subjects were randomized to immediate treatment or waitlist control, with all eventually receiving PAP. Participants had one, two, or three psilocybin sessions with a fixed dose of 25 mg. Each dose was accompanied by preparation and integration psychotherapy sessions. Acceptability, safety, tolerability, and efficacy were evaluated (this study was registered at ClinicalTrials.gov: NCT05029466).
    Findings: Participants were randomized to immediate treatment (n = 16) or delayed treatment (n = 14). 29/30 were retained to the week-2 primary endpoint. Adverse events were transient, with no serious adverse events. Greater reductions in depression severity as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) were observed in the immediate treatment arm compared to the waitlist period arm with a large hedge's g effect size of 1.07 (p < 0.01). Repeated doses were associated with further reductions in MADRS scores compared to baseline.
    Conclusions: PAP was feasible in complex patients with preliminary antidepressant efficacy and adequate safety and tolerability. Repeated doses were associated with greater reductions in depression severity.
    Funding: This work was funded by Brain and Cognition Discovery Foundation (BCDF), Usona, and Braxia Scientific.
    MeSH term(s) Adult ; Humans ; Psilocybin/adverse effects ; Depressive Disorder, Major/drug therapy ; Depressive Disorder, Major/chemically induced ; Depressive Disorder, Treatment-Resistant/drug therapy ; Antidepressive Agents/adverse effects ; Psychotherapy
    Chemical Substances Psilocybin (2RV7212BP0) ; Antidepressive Agents
    Language English
    Publishing date 2024-02-14
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article
    ISSN 2666-6340
    ISSN (online) 2666-6340
    DOI 10.1016/j.medj.2024.01.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top